新辅助帕博利珠单抗治疗早期三阴性乳腺癌的真实世界有效性与安全性:系统评价与荟萃分析。
完整摘要 · 中文译文
背景:早期三阴性乳腺癌(esTNBC)是一种侵袭性恶性肿瘤,新辅助化疗仍是其标准治疗方法。随机试验已证实,加用帕博利珠单抗可提高病理完全缓解率。然而,试验人群可能无法完全反映常规临床实践。描述新辅助帕博利珠单抗在早期TNBC中真实世界有效性和安全性的证据尚未被系统综合。因此,本系统评价和荟萃分析评估了基于帕博利珠单抗的新辅助方案相关的真实世界结局。 方法:对PubMed、Embase、Scopus和Cochrane Library进行了系统检索,检索截至2025年8月14日(更新至2026年2月7日)。我们纳入了比较新辅助帕博利珠单抗联合化疗与单纯化疗用于esTNBC患者的前瞻性和回顾性队列研究。两名评价者独立筛选研究、提取数据,并使用纽卡斯尔-渥太华量表评估方法学质量。采用随机效应模型进行荟萃分析。使用GRADE方法评估证据确定性。 结果:共纳入5项观察性研究(N = 1,501,平均年龄49.5至57.8岁)。汇总分析提示,与单纯化疗相比,新辅助帕博利珠单抗联合化疗可能与更高的病理完全缓解可能性相关(RR:1.52,95% CI 1.29-1.80)。帕博利珠单抗的使用还可能降低接受腋窝淋巴结清扫的可能性(RR :0.65,95% CI 0.50-0.86)。在至首次辅助治疗时间或术后并发症方面未观察到明显差异。帕博利珠单抗最常报告的免疫相关不良事件包括甲状腺功能障碍和肾上腺功能不全。所有结局的证据确定性均评为极低。 结论:极低确定性的证据似乎提示,在常规临床实践中,对于早期三阴性乳腺癌(esTNBC),在新辅助化疗基础上加用帕博利珠单抗可能提高达到病理学完全缓解的概率,并可能与腋窝淋巴结清扫可能性降低相关,而围手术期并发症无明显增加。然而,对这些效应估计值的信心有限,主要归因于观察性研究固有的局限性。这些发现虽然与随机试验证据一致,但不应被解读为确定性结论。本综述强调需要持续进行安全性监测和设计良好的比较研究,以加强帕博利珠单抗在该情境下真实世界使用的证据基础。 临床试验编号:不适用。 注册:开放科学框架(DOI:10.17605/OSF.IO/N7YJK)。
完整摘要 · 英文原文
BACKGROUND: Early-stage triple-negative breast cancer (esTNBC) is an aggressive malignancy for which neoadjuvant chemotherapy remains the standard approach. Randomized trials have demonstrated improved pathologic complete response with the addition of pembrolizumab. However, trial populations may not fully reflect routine clinical practice. Evidence describing the real-world effectiveness and safety of neoadjuvant pembrolizumab in early-stage TNBC has not been systematically synthesized. This systematic review and meta-analysis therefore evaluated real-world outcomes associated with pembrolizumab-based neoadjuvant regimens. METHODS: A systematic search of PubMed, Embase, Scopus, and the Cochrane Library were searched to August 14, 2025 (updated: February 7, 2026). We included prospective and retrospective cohort studies comparing neoadjuvant pembrolizumab plus chemotherapy to chemotherapy alone in patients with esTNBC. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the Newcastle-Ottawa Scale. Meta-analyses were performed using a random-effects model. Certainty of evidence was evaluated using the GRADE approach. RESULTS: Five observational studies (N = 1,501, mean ages 49.5 to 57.8 years) were included. Pooled analysis suggested that compared to chemotherapy alone, neoadjuvant pembrolizumab plus chemotherapy could be associated with a higher likelihood of achieving pathologic complete response (RR:1.52, 95% CI 1.29-1.80). Pembrolizumab use may also reduce the likelihood of undergoing axillary lymph node dissections (RR:0.65, 95% CI 0.50-0.86). No clear differences were observed for time to first adjuvant therapy or postoperative complications. The most frequently reported immune-related adverse events with pembrolizumab included thyroid dysfunction and adrenal insufficiency. Evidence certainty was rated very low for all outcomes. CONCLUSION: Very-low certainty evidence appears to suggest that in routine clinical practice, the addition of pembrolizumab to neoadjuvant chemotherapy for esTNBC could increase the probability of achieving pathologic complete response and may be associated with a reduced likelihood of axillary lymph node dissection, with no clear increase in perioperative complications. However, confidence in these effect estimates is limited mainly due to inherent limitations in observational studies. These findings, although consistent with randomized trial evidence, should not be interpreted as definitive. This review highlights the need for ongoing safety surveillance and well-designed comparative studies to strengthen the evidence base for real-world use of pembrolizumab in this setting. CLINICAL TRIALS NO: Not Applicable. REGISTRATION: Open Science Framework (DOI: 10.17605/OSF.IO/N7YJK).